These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22093205)

  • 1. Safety and efficacy of adjusted-dose eptifibatide in patients with acute coronary syndromes and reduced renal function.
    Melloni C; James SK; White JA; Giugliano RP; Harrington RA; Huber K; Tricoci P; Armstrong PW; Van de Werf F; Montalescot G; Califf RM; Newby LK
    Am Heart J; 2011 Nov; 162(5):884-892.e1. PubMed ID: 22093205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early versus delayed, provisional eptifibatide in acute coronary syndromes.
    Giugliano RP; White JA; Bode C; Armstrong PW; Montalescot G; Lewis BS; van 't Hof A; Berdan LG; Lee KL; Strony JT; Hildemann S; Veltri E; Van de Werf F; Braunwald E; Harrington RA; Califf RM; Newby LK;
    N Engl J Med; 2009 May; 360(21):2176-90. PubMed ID: 19332455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Upstream clopidogrel use and the efficacy and safety of early eptifibatide treatment in patients with acute coronary syndrome: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome (EARLY ACS) trial.
    Wang TY; White JA; Tricoci P; Giugliano RP; Zeymer U; Harrington RA; Montalescot G; James SK; Van de Werf F; Armstrong PW; Braunwald E; Califf RM; Newby LK
    Circulation; 2011 Feb; 123(7):722-30. PubMed ID: 21300952
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sex differences in major bleeding with glycoprotein IIb/IIIa inhibitors: results from the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) initiative.
    Alexander KP; Chen AY; Newby LK; Schwartz JB; Redberg RF; Hochman JS; Roe MT; Gibler WB; Ohman EM; Peterson ED;
    Circulation; 2006 Sep; 114(13):1380-7. PubMed ID: 16982940
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upstream use of small-molecule glycoprotein iib/iiia inhibitors in patients with non-ST-segment elevation acute coronary syndromes: a systematic overview of randomized clinical trials.
    Tricoci P; Newby LK; Hasselblad V; Kong DF; Giugliano RP; White HD; Théroux P; Stone GW; Moliterno DJ; Van de Werf F; Armstrong PW; Prabhakaran D; Rasoul S; Bolognese L; Durand E; Braunwald E; Califf RM; Harrington RA
    Circ Cardiovasc Qual Outcomes; 2011 Jul; 4(4):448-58. PubMed ID: 21712522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Age, treatment, and outcomes in high-risk non-ST-segment elevation acute coronary syndrome patients: insights from the EARLY ACS trial.
    Lopes RD; White JA; Tricoci P; White HD; Armstrong PW; Braunwald E; Giugliano RP; Harrington RA; Lewis BS; Brogan GX; Gibson CM; Califf RM; Newby LK
    Int J Cardiol; 2013 Sep; 167(6):2580-7. PubMed ID: 22795720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Routine early eptifibatide versus delayed provisional use at percutaneous coronary intervention in high-risk non-ST-segment elevation acute coronary syndromes patients: an analysis from the Early Glycoprotein IIb/IIIa Inhibition in Non-ST-Segment Elevation Acute Coronary Syndrome trial.
    Bagai A; White JA; Lokhnygina Y; Giugliano RP; Van de Werf F; Montalescot G; Armstrong PW; Tricoci P; Gibson CM; Califf RM; Harrington RA; Newby LK
    Am Heart J; 2013 Sep; 166(3):466-73. PubMed ID: 24016495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic and pharmacodynamic properties of eptifibatide in subjects with normal or impaired renal function.
    Gretler DD; Guerciolini R; Williams PJ
    Clin Ther; 2004 Mar; 26(3):390-8. PubMed ID: 15110131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjusting eptifibatide doses for renal impairment: a model of dosing agreement among various methods of estimating creatinine clearance.
    Healy MF; Speroni KG; Eugenio KR; Murphy PM
    Ann Pharmacother; 2012 Apr; 46(4):477-83. PubMed ID: 22474135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
    Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
    Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relation of renal function to ischemic and bleeding outcomes with 2 different glycoprotein IIb/IIIa inhibitors: the do Tirofiban and ReoPro Give Similar Efficacy Outcome (TARGET) trial.
    Berger PB; Best PJ; Topol EJ; White J; DiBattiste PM; Chan AW; Kristensen SD; Herrmann HC; Moliterno DJ
    Am Heart J; 2005 May; 149(5):869-75. PubMed ID: 15894970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial.
    Steg PG; Mehta SR; Pollack CV; Bode C; Cohen M; French WJ; Hoekstra J; Rao SV; Ruzyllo W; Ruiz-Nodar JM; Sabaté M; Widimsky P; Kiss RG; Navarro Estrada JL; Hod H; Kerkar P; Guneri S; Sezer M; Ruda M; Nicolau JC; Cavallini C; Ebrahim I; Petrov I; Kim JH; Jeong MH; Ramos Lopez GA; Laanmets P; Kovar F; Gaudin C; Fanouillere KC; Minini P; Hoffman EB; Moryusef A; Wiviott SD; Sabatine MS;
    JAMA; 2013 Sep; 310(11):1145-55. PubMed ID: 23995608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glycoprotein IIb/IIIa inhibitors in patients with renal insufficiency undergoing percutaneous coronary intervention.
    Anderson JR; Riding D
    Cardiol Rev; 2008; 16(4):213-8. PubMed ID: 18562812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The early glycoprotein IIb/IIIa inhibition in non-ST-segment elevation acute coronary syndrome (EARLY ACS) trial: a randomized placebo-controlled trial evaluating the clinical benefits of early front-loaded eptifibatide in the treatment of patients with non-ST-segment elevation acute coronary syndrome--study design and rationale.
    Giugliano RP; Newby LK; Harrington RA; Gibson CM; Van de Werf F; Armstrong P; Montalescot G; Gilbert J; Strony JT; Califf RM; Braunwald E;
    Am Heart J; 2005 Jun; 149(6):994-1002. PubMed ID: 15976780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fasting glucose, NT-proBNP, treatment with eptifibatide, and outcomes in non-ST-segment elevation acute coronary syndromes: An analysis from EARLY ACS.
    Farhan S; Clare RM; Jarai R; Giugliano RP; Lokhnygina Y; Harrington RA; Kristin Newby L; Huber K
    Int J Cardiol; 2017 Apr; 232():264-270. PubMed ID: 28089149
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practice patterns and clinical outcomes among non-ST-segment elevation acute coronary syndrome (NSTE-ACS) patients presenting to primary and tertiary hospitals: insights from the EARLY glycoprotein IIb/IIIa inhibition in NSTE-ACS (EARLY-ACS) trial.
    Toleva O; Westerhout CM; Senaratne MP; Bode C; Lindroos M; Sulimov VA; Montalescot G; Newby LK; Giugliano RP; Van de Werf F; Armstrong PW
    Catheter Cardiovasc Interv; 2014 Nov; 84(6):934-42. PubMed ID: 24976083
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy.
    Steg PG; Mehta SR; Pollack CV; Bode C; Gaudin C; Fanouillere K; Moryusef A; Wiviott SD; Sabatine MS
    Am Heart J; 2012 Dec; 164(6):817-24.e13. PubMed ID: 23194481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS.
    Hess CN; Schulte PJ; Newby LK; Steg PG; Dalby AJ; Schweiger MJ; Lewis BS; Armstrong PW; Califf RM; van de Werf F; Harrington RA
    Eur Heart J Acute Cardiovasc Care; 2013 Sep; 2(3):246-55. PubMed ID: 24222836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The clinical use of the GPIIb/IIIa inhibitors eptifibatide and tirofiban in the treatment of acute coronary syndromes of the "non-ST elevation" type].
    Galli M; Maggioni AP; Vassanelli C; Tavazzi L
    Ital Heart J Suppl; 2000 Feb; 1(2):202-11. PubMed ID: 10731377
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiographic outcomes with early eptifibatide therapy in non-ST-segment elevation acute coronary syndrome (from the EARLY ACS Trial).
    Kunadian V; Giugliano RP; Newby LK; Zorkun C; Guo J; Bagai A; Montalescot G; Braunwald E; Califf RM; Van de Werf F; Armstrong PW; Harrington R; Gibson CM
    Am J Cardiol; 2014 Apr; 113(8):1297-305. PubMed ID: 24607027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.